Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY2584702 in Japanese Patients with Solid Tumors
jRCT2080221292Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ly2584702 in Nonhematologic neoplasms, sponsored by Eli Lilly and Company. Primary endpoint: Safety and tolerability of LY2584702.
02
Drugs
ly2584702
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221292.